Vanguard Group Inc. increased its stake in Chemed Co. (NYSE:CHE - Free Report) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,669,121 shares of the company's stock after acquiring an additional 2,568 shares during the period. Vanguard Group Inc. owned approximately 11.09% of Chemed worth $884,300,000 at the end of the most recent reporting period.
A number of other hedge funds have also made changes to their positions in the stock. Raymond James Financial Inc. bought a new position in Chemed during the 4th quarter valued at $42,023,000. HighTower Advisors LLC boosted its stake in Chemed by 78.0% during the third quarter. HighTower Advisors LLC now owns 3,730 shares of the company's stock valued at $2,246,000 after buying an additional 1,634 shares in the last quarter. XTX Topco Ltd grew its holdings in Chemed by 111.5% during the third quarter. XTX Topco Ltd now owns 2,843 shares of the company's stock worth $1,709,000 after acquiring an additional 1,499 shares during the period. Geode Capital Management LLC raised its position in Chemed by 4.9% in the third quarter. Geode Capital Management LLC now owns 335,443 shares of the company's stock worth $201,820,000 after acquiring an additional 15,791 shares in the last quarter. Finally, Signal Advisors Wealth LLC lifted its holdings in Chemed by 60.7% in the 4th quarter. Signal Advisors Wealth LLC now owns 4,995 shares of the company's stock valued at $2,647,000 after acquiring an additional 1,886 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company's stock.
Chemed Trading Up 0.8 %
Shares of Chemed stock traded up $4.79 on Thursday, reaching $619.47. 138,992 shares of the company were exchanged, compared to its average volume of 95,171. Chemed Co. has a fifty-two week low of $512.12 and a fifty-two week high of $639.61. The firm has a market capitalization of $9.07 billion, a price-to-earnings ratio of 31.30, a price-to-earnings-growth ratio of 2.15 and a beta of 0.43. The stock has a fifty day moving average price of $579.29 and a 200-day moving average price of $567.98.
Chemed Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Monday, February 24th were paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date of this dividend was Monday, February 24th. Chemed's dividend payout ratio is presently 10.05%.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the stock. Royal Bank of Canada lifted their price objective on shares of Chemed from $633.00 to $667.00 and gave the stock an "outperform" rating in a research note on Friday, March 14th. StockNews.com upgraded shares of Chemed from a "hold" rating to a "buy" rating in a research report on Friday, March 7th.
View Our Latest Report on CHE
Insider Buying and Selling at Chemed
In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $593.67, for a total transaction of $1,187,340.00. Following the transaction, the chief executive officer now directly owns 102,679 shares of the company's stock, valued at approximately $60,957,441.93. The trade was a 1.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.32% of the company's stock.
About Chemed
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Featured Stories

Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.